Therefore, the current study tests whether EGCG could be used as an alternative strategy to target the PD-1-PD-L1/PD-L2 signaling cascade to evoke an anti-tumor immune response in melanoma. The gene discussed is PDCD1LG2; the disease is neoplasm.